{"id":13708,"date":"2023-06-12T07:25:08","date_gmt":"2023-06-12T07:25:08","guid":{"rendered":"https:\/\/www.sygnaturediscovery.com\/sygnature-discovery-lance-son-modele-lps-in-vivo-pour-profiler-les-medicaments-anti-inflammatoires-en-phase-precoce\/"},"modified":"2026-02-11T09:51:13","modified_gmt":"2026-02-11T09:51:13","slug":"sygnature-discovery-lance-son-modele-lps-in-vivo-pour-profiler-les-medicaments-anti-inflammatoires-en-phase-precoce","status":"publish","type":"post","link":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-lance-son-modele-lps-in-vivo-pour-profiler-les-medicaments-anti-inflammatoires-en-phase-precoce\/","title":{"rendered":"Sygnature Discovery lance son mod\u00e8le LPS <span style=\"font-style:italic;\">in vivo<\/span> pour profiler les m\u00e9dicaments anti-inflammatoires en phase pr\u00e9coce."},"content":{"rendered":"<h2><span style=\"font-size: 14pt;\"><strong>Sygnature Discovery a mis au point un <span aria-label=\"Rich text content control\">mod\u00e8le<\/span> <span aria-label=\"Rich text content control\"><span style=\"color: #00ccff;\"><a style=\"color: #00ccff;\" href=\"https:\/\/info.sygnaturediscovery.com\/lps-model\" target=\"_blank\" rel=\"noopener\">LPS<\/a><\/span> <i>in vivo<\/i><\/span> d\u2019inflammation qui peut aider \u00e0 comprendre les affections neuro-inflammatoires limitant l\u2019esp\u00e9rance de vie comme la maladie de Parkinson, la scl\u00e9rose en plaques, la maladie d\u2019Alzheimer et les traumatismes cr\u00e2niens, et \u00e0 identifier de nouvelles cibles th\u00e9rapeutiques.  <\/strong><\/span><\/h2>\n<p><span style=\"font-size: 14pt;\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft wp-image-14149 size-medium\" src=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/LPS-carousel-Recovered_02.png\" alt=\"\" width=\"300\" height=\"300\">Le mod\u00e8le LPS <i>in vivo<\/i> soutient la d\u00e9couverte pr\u00e9coce de m\u00e9dicaments anti-inflammatoires <span aria-label=\"Rich text content control\">dans<\/span> la neuroinflammation, les reins et l\u2019inflammation syst\u00e9mique.  <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">L\u2019int\u00e9gration d\u2019\u00e9tudes sur l\u2019inflammation r\u00e9nale et la neuroinflammation au mod\u00e8le LPS de Sygnature Discovery le distingue des mod\u00e8les conventionnels, offrant des perspectives pr\u00e9cieuses sur l\u2019interaction complexe de l\u2019inflammation dans diff\u00e9rents organes. Cette capacit\u00e9 unique permet aux chercheurs d\u2019identifier de nouveaux m\u00e9canismes d\u2019action m\u00e9dicamenteux, d\u2019\u00e9valuer l\u2019efficacit\u00e9 des m\u00e9dicaments et d\u2019approfondir notre compr\u00e9hension des maladies r\u00e9nales et neuro-inflammatoires, favorisant ainsi le d\u00e9veloppement de th\u00e9rapies cibl\u00e9es pour les patients dont les besoins ne sont pas satisfaits.   <\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><span aria-label=\"Rich text content control paragraph\">Ce mod\u00e8le permet \u00e9galement de comprendre la pharmacologie et les processus qui sous-tendent l\u2019inflammation syst\u00e9mique, et s\u2019appuie sur les capacit\u00e9s <i>in vitro<\/i> existantes de Sygnature Discovery pour renforcer la validation des cibles m\u00e9dicamenteuses et la transposition des r\u00e9sultats <i>in vitro<\/i> aux <i>r\u00e9sultats in vivo.<\/i> Il mesure les principales cytokines pro-inflammatoires dans le sang et fournit un syst\u00e8me mod\u00e8le utile pour \u00e9valuer rapidement l\u2019efficacit\u00e9 de nouveaux m\u00e9dicaments anti-inflammatoires lors des premi\u00e8res phases de la d\u00e9couverte de m\u00e9dicaments.<\/span> <\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><span aria-label=\"Rich text content control\">Commentant les avantages du mod\u00e8le,<\/span> le Dr John Unitt, <span aria-label=\"Rich text content control\">vice<\/span> \u2013 <span aria-label=\"Rich text content control\">pr\u00e9sident<\/span> de l\u2019inflammation et de l\u2019immunologie chez Sygnature Discovery, a <span aria-label=\"Rich text content control\">d\u00e9clar\u00e9<\/span> :  <\/span><\/p>\n<blockquote><p><em><span style=\"color: #003366; font-size: 18pt;\">\u00ab Une \u00e9tape cruciale de la d\u00e9couverte de m\u00e9dicaments consiste \u00e0 transposer avec succ\u00e8s l\u2019effet d\u2019un m\u00e9dicament sur la fonction cellulaire in vitro \u00e0 son efficacit\u00e9 dans un mod\u00e8le de maladie in vivo. Le mod\u00e8le LPS in vivo de Sygnature constitue cette premi\u00e8re \u00e9tape pour d\u00e9terminer l\u2019efficacit\u00e9 d\u2019un nouvel anti-inflammatoire. La mise en place de ce premier mod\u00e8le d\u2019inflammation in vivo repr\u00e9sente un d\u00e9but prometteur, mais ne marque que le point de d\u00e9part d\u2019une s\u00e9rie de nouveaux mod\u00e8les pr\u00e9vus pour tester un \u00e9ventail plus large de m\u00e9dicaments et de m\u00e9canismes immunomodulateurs. \u00bb  <\/span><\/em><\/p><\/blockquote>\n<p><span style=\"font-size: 14pt;\">Le Dr Max Mirza, vice-pr\u00e9sident des neurosciences chez Sygnature Discovery, a <span aria-label=\"Rich text content control\">ajout\u00e9<\/span> :  <\/span><span data-ccp-props=\"{\"> <\/span><\/p>\n<blockquote><p><em><span style=\"color: #003366; font-size: 18pt;\">\u00ab La neuroinflammation, tout comme l\u2019inflammation syst\u00e9mique et r\u00e9nale, implique de nombreux m\u00e9diateurs inflammatoires communs (cytokines, chimiokines). La collaboration inter-\u00e9quipes th\u00e9rapeutiques chez Sygnature pour \u00e9tablir le mod\u00e8le LPS et mesurer ces m\u00e9diateurs inflammatoires dans diff\u00e9rentes parties du corps permet \u00e0 nos clients d\u2019obtenir une r\u00e9ponse plus globale \u00e0 leurs questions scientifiques. Qu\u2019il s\u2019agisse d\u2019 <span aria-label=\"Rich text content control\">une<\/span> meilleure compr\u00e9hension <span aria-label=\"Rich text content control\">du<\/span> m\u00e9canisme d\u2019action, <span aria-label=\"Rich text content control\">du<\/span> r\u00f4le d\u2019une cible sur les processus inflammatoires dans plusieurs compartiments corporels simultan\u00e9ment, ou de la pertinence pour l\u2019efficacit\u00e9 d\u2019un m\u00e9dicament, cette approche unique permet \u00e0 nos clients de d\u00e9terminer si une action sur l\u2019inflammation syst\u00e9mique peut influencer la neuroinflammation et si les m\u00e9diateurs inflammatoires syst\u00e9miques constituent des biomarqueurs potentiels de la neuroinflammation. \u00bb    <\/span><\/em><\/p><\/blockquote>\n<p><span style=\"font-size: 14pt;\">Pour en savoir plus, visitez le site Web de Sygnature Discovery pour obtenir des d\u00e9tails sur le <strong><span style=\"color: #00ccff;\"><a style=\"color: #00ccff;\" href=\"https:\/\/info.sygnaturediscovery.com\/lps-model\" target=\"_blank\" rel=\"noopener\">mod\u00e8le LPS<\/a><\/span><\/strong> , ou rencontrez <strong><span style=\"color: #00ccff;\"><a style=\"color: #00ccff;\" href=\"https:\/\/www.sygnaturediscovery.com\/team-members\/dr-john-unitt\/\" target=\"_blank\" rel=\"noopener\">John Unitt<\/a><\/span><\/strong> lors du prochain <a href=\"https:\/\/wcp2023.org\/\" target=\"_blank\" rel=\"noopener\"><em><strong>Congr\u00e8s mondial de recherche fondamentale et clinique<\/strong><\/em><\/a> \u00e0 Glasgow, du 2 au 7 juillet, o\u00f9 son \u00e9quipe pr\u00e9sentera des travaux sur le sujet.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":13709,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"category":[817,900,902,818,816],"tags":[916,904,909,905,918,824,903,906,914,920,921,845,917,907,912,910,913,911,919,922,915,923,908],"class_list":["post-13708","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-domaines-therapeutiques","category-ii","category-modeles-d39inflammation-et-d39immunologie","category-neuroscience","category-pharmacologie-in-vivo","tag-affections-neuro-inflammatoires","tag-chimiokines","tag-cibles-medicamenteuses","tag-cytokines","tag-cytokines-pro-inflammatoires","tag-decouverte-de-la-signature","tag-decouverte-de-medicaments-anti-inflammatoires","tag-efficacite-du-medicament","tag-inflammation-renale","tag-inflammation-systemique","tag-interventions-therapeutiques","tag-maladie-dalzheimer","tag-maladie-de-parkinson","tag-mecanismes-daction-des-medicaments","tag-mediateurs-de-linflammation","tag-medicaments-immunomodulateurs","tag-modele-dinflammation","tag-modele-lps-in-vivo","tag-recherche-scientifique","tag-recherche-translationnelle","tag-sclerose-en-plaques","tag-traumatismes-craniens","tag-validation-des-cibles-medicamenteuses"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sygnature Discovery lance son mod\u00e8le LPS in vivo pour profiler les m\u00e9dicaments anti-inflammatoires en phase pr\u00e9coce. - Sygnature<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-lance-son-modele-lps-in-vivo-pour-profiler-les-medicaments-anti-inflammatoires-en-phase-precoce\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sygnature Discovery lance son mod\u00e8le LPS in vivo pour profiler les m\u00e9dicaments anti-inflammatoires en phase pr\u00e9coce. - Sygnature\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-lance-son-modele-lps-in-vivo-pour-profiler-les-medicaments-anti-inflammatoires-en-phase-precoce\/\" \/>\n<meta property=\"og:site_name\" content=\"Sygnature\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-12T07:25:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-11T09:51:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/LPS-carousel-Recovered_02.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"pnpd-admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"pnpd-admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-discovery-lance-son-modele-lps-in-vivo-pour-profiler-les-medicaments-anti-inflammatoires-en-phase-precoce\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-discovery-lance-son-modele-lps-in-vivo-pour-profiler-les-medicaments-anti-inflammatoires-en-phase-precoce\\\/\"},\"author\":{\"name\":\"pnpd-admin\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/person\\\/9c173ed9f4225ab61ea895ac3a939448\"},\"headline\":\"Sygnature Discovery lance son mod\u00e8le LPS in vivo pour profiler les m\u00e9dicaments anti-inflammatoires en phase pr\u00e9coce.\",\"datePublished\":\"2023-06-12T07:25:08+00:00\",\"dateModified\":\"2026-02-11T09:51:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-discovery-lance-son-modele-lps-in-vivo-pour-profiler-les-medicaments-anti-inflammatoires-en-phase-precoce\\\/\"},\"wordCount\":623,\"publisher\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-discovery-lance-son-modele-lps-in-vivo-pour-profiler-les-medicaments-anti-inflammatoires-en-phase-precoce\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/LPS-carousel-Recovered_02.png\",\"keywords\":[\"affections neuro-inflammatoires\",\"chimiokines\",\"cibles m\u00e9dicamenteuses\",\"cytokines\",\"cytokines pro-inflammatoires\",\"D\u00e9couverte de la signature\",\"d\u00e9couverte de m\u00e9dicaments anti-inflammatoires\",\"efficacit\u00e9 du m\u00e9dicament\",\"inflammation r\u00e9nale\",\"inflammation syst\u00e9mique\",\"interventions th\u00e9rapeutiques\",\"maladie d'Alzheimer\",\"maladie de Parkinson\",\"m\u00e9canismes d'action des m\u00e9dicaments\",\"m\u00e9diateurs de l'inflammation\",\"m\u00e9dicaments immunomodulateurs\",\"mod\u00e8le d'inflammation\",\"Mod\u00e8le LPS in vivo\",\"recherche scientifique\",\"recherche translationnelle\",\"scl\u00e9rose en plaques\",\"traumatismes cr\u00e2niens\",\"validation des cibles m\u00e9dicamenteuses\"],\"articleSection\":[\"Domaines th\u00e9rapeutiques\",\"I&amp;I\",\"Mod\u00e8les d&amp;#39;inflammation et d&amp;#39;immunologie\",\"Neuroscience\",\"pharmacologie in vivo\"],\"inLanguage\":\"fr-CA\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-discovery-lance-son-modele-lps-in-vivo-pour-profiler-les-medicaments-anti-inflammatoires-en-phase-precoce\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-discovery-lance-son-modele-lps-in-vivo-pour-profiler-les-medicaments-anti-inflammatoires-en-phase-precoce\\\/\",\"name\":\"Sygnature Discovery lance son mod\u00e8le LPS in vivo pour profiler les m\u00e9dicaments anti-inflammatoires en phase pr\u00e9coce. - Sygnature\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-discovery-lance-son-modele-lps-in-vivo-pour-profiler-les-medicaments-anti-inflammatoires-en-phase-precoce\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-discovery-lance-son-modele-lps-in-vivo-pour-profiler-les-medicaments-anti-inflammatoires-en-phase-precoce\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/LPS-carousel-Recovered_02.png\",\"datePublished\":\"2023-06-12T07:25:08+00:00\",\"dateModified\":\"2026-02-11T09:51:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-discovery-lance-son-modele-lps-in-vivo-pour-profiler-les-medicaments-anti-inflammatoires-en-phase-precoce\\\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-discovery-lance-son-modele-lps-in-vivo-pour-profiler-les-medicaments-anti-inflammatoires-en-phase-precoce\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-discovery-lance-son-modele-lps-in-vivo-pour-profiler-les-medicaments-anti-inflammatoires-en-phase-precoce\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/LPS-carousel-Recovered_02.png\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/LPS-carousel-Recovered_02.png\",\"width\":1080,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-discovery-lance-son-modele-lps-in-vivo-pour-profiler-les-medicaments-anti-inflammatoires-en-phase-precoce\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/page-daccueil\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sygnature Discovery lance son mod\u00e8le LPS in vivo pour profiler les m\u00e9dicaments anti-inflammatoires en phase pr\u00e9coce.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"name\":\"Sygnature Discovery\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\"},\"alternateName\":\"Sygnature\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\",\"name\":\"Sygnature\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"width\":1,\"height\":1,\"caption\":\"Sygnature\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/person\\\/9c173ed9f4225ab61ea895ac3a939448\",\"name\":\"pnpd-admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/052476d339a267f4be89460f64dd24ba52137529feafa9cf45d6e8b2b62cda8b?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/052476d339a267f4be89460f64dd24ba52137529feafa9cf45d6e8b2b62cda8b?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/052476d339a267f4be89460f64dd24ba52137529feafa9cf45d6e8b2b62cda8b?s=96&d=mm&r=g\",\"caption\":\"pnpd-admin\"},\"sameAs\":[\"http:\\\/\\\/www.sygnaturediscovery.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sygnature Discovery lance son mod\u00e8le LPS in vivo pour profiler les m\u00e9dicaments anti-inflammatoires en phase pr\u00e9coce. - Sygnature","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-lance-son-modele-lps-in-vivo-pour-profiler-les-medicaments-anti-inflammatoires-en-phase-precoce\/","og_locale":"fr_CA","og_type":"article","og_title":"Sygnature Discovery lance son mod\u00e8le LPS in vivo pour profiler les m\u00e9dicaments anti-inflammatoires en phase pr\u00e9coce. - Sygnature","og_url":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-lance-son-modele-lps-in-vivo-pour-profiler-les-medicaments-anti-inflammatoires-en-phase-precoce\/","og_site_name":"Sygnature","article_published_time":"2023-06-12T07:25:08+00:00","article_modified_time":"2026-02-11T09:51:13+00:00","og_image":[{"width":1080,"height":1080,"url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/LPS-carousel-Recovered_02.png","type":"image\/png"}],"author":"pnpd-admin","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"pnpd-admin","Estimation du temps de lecture":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-lance-son-modele-lps-in-vivo-pour-profiler-les-medicaments-anti-inflammatoires-en-phase-precoce\/#article","isPartOf":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-lance-son-modele-lps-in-vivo-pour-profiler-les-medicaments-anti-inflammatoires-en-phase-precoce\/"},"author":{"name":"pnpd-admin","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/person\/9c173ed9f4225ab61ea895ac3a939448"},"headline":"Sygnature Discovery lance son mod\u00e8le LPS in vivo pour profiler les m\u00e9dicaments anti-inflammatoires en phase pr\u00e9coce.","datePublished":"2023-06-12T07:25:08+00:00","dateModified":"2026-02-11T09:51:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-lance-son-modele-lps-in-vivo-pour-profiler-les-medicaments-anti-inflammatoires-en-phase-precoce\/"},"wordCount":623,"publisher":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-lance-son-modele-lps-in-vivo-pour-profiler-les-medicaments-anti-inflammatoires-en-phase-precoce\/#primaryimage"},"thumbnailUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/LPS-carousel-Recovered_02.png","keywords":["affections neuro-inflammatoires","chimiokines","cibles m\u00e9dicamenteuses","cytokines","cytokines pro-inflammatoires","D\u00e9couverte de la signature","d\u00e9couverte de m\u00e9dicaments anti-inflammatoires","efficacit\u00e9 du m\u00e9dicament","inflammation r\u00e9nale","inflammation syst\u00e9mique","interventions th\u00e9rapeutiques","maladie d'Alzheimer","maladie de Parkinson","m\u00e9canismes d'action des m\u00e9dicaments","m\u00e9diateurs de l'inflammation","m\u00e9dicaments immunomodulateurs","mod\u00e8le d'inflammation","Mod\u00e8le LPS in vivo","recherche scientifique","recherche translationnelle","scl\u00e9rose en plaques","traumatismes cr\u00e2niens","validation des cibles m\u00e9dicamenteuses"],"articleSection":["Domaines th\u00e9rapeutiques","I&amp;I","Mod\u00e8les d&amp;#39;inflammation et d&amp;#39;immunologie","Neuroscience","pharmacologie in vivo"],"inLanguage":"fr-CA"},{"@type":"WebPage","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-lance-son-modele-lps-in-vivo-pour-profiler-les-medicaments-anti-inflammatoires-en-phase-precoce\/","url":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-lance-son-modele-lps-in-vivo-pour-profiler-les-medicaments-anti-inflammatoires-en-phase-precoce\/","name":"Sygnature Discovery lance son mod\u00e8le LPS in vivo pour profiler les m\u00e9dicaments anti-inflammatoires en phase pr\u00e9coce. - Sygnature","isPartOf":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-lance-son-modele-lps-in-vivo-pour-profiler-les-medicaments-anti-inflammatoires-en-phase-precoce\/#primaryimage"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-lance-son-modele-lps-in-vivo-pour-profiler-les-medicaments-anti-inflammatoires-en-phase-precoce\/#primaryimage"},"thumbnailUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/LPS-carousel-Recovered_02.png","datePublished":"2023-06-12T07:25:08+00:00","dateModified":"2026-02-11T09:51:13+00:00","breadcrumb":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-lance-son-modele-lps-in-vivo-pour-profiler-les-medicaments-anti-inflammatoires-en-phase-precoce\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-lance-son-modele-lps-in-vivo-pour-profiler-les-medicaments-anti-inflammatoires-en-phase-precoce\/"]}]},{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-lance-son-modele-lps-in-vivo-pour-profiler-les-medicaments-anti-inflammatoires-en-phase-precoce\/#primaryimage","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/LPS-carousel-Recovered_02.png","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/LPS-carousel-Recovered_02.png","width":1080,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-lance-son-modele-lps-in-vivo-pour-profiler-les-medicaments-anti-inflammatoires-en-phase-precoce\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sygnaturediscovery.com\/fr\/page-daccueil\/"},{"@type":"ListItem","position":2,"name":"Sygnature Discovery lance son mod\u00e8le LPS in vivo pour profiler les m\u00e9dicaments anti-inflammatoires en phase pr\u00e9coce."}]},{"@type":"WebSite","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","name":"Sygnature Discovery","description":"","publisher":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization"},"alternateName":"Sygnature","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sygnaturediscovery.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization","name":"Sygnature","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","width":1,"height":1,"caption":"Sygnature"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/person\/9c173ed9f4225ab61ea895ac3a939448","name":"pnpd-admin","image":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/secure.gravatar.com\/avatar\/052476d339a267f4be89460f64dd24ba52137529feafa9cf45d6e8b2b62cda8b?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/052476d339a267f4be89460f64dd24ba52137529feafa9cf45d6e8b2b62cda8b?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/052476d339a267f4be89460f64dd24ba52137529feafa9cf45d6e8b2b62cda8b?s=96&d=mm&r=g","caption":"pnpd-admin"},"sameAs":["http:\/\/www.sygnaturediscovery.com"]}]}},"_links":{"self":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/posts\/13708","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/comments?post=13708"}],"version-history":[{"count":0,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/posts\/13708\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media\/13709"}],"wp:attachment":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media?parent=13708"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/category?post=13708"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/tags?post=13708"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}